China SXT Pharmaceuticals, Inc. (SXTC): Price and Financial Metrics

China SXT Pharmaceuticals, Inc. (SXTC)

Today's Latest Price: $0.31 USD

0.03 (-9.85%)

Updated Dec 2 4:00pm

Add SXTC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SXTC Stock Summary

  • With a year-over-year growth in debt of 1,645.91%, China SXT Pharmaceuticals Inc's debt growth rate surpasses 98.57% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, China SXT Pharmaceuticals Inc is reporting a growth rate of -532.36%; that's higher than just 3.91% of US stocks.
  • As for revenue growth, note that SXTC's revenue has grown -74.91% over the past 12 months; that beats the revenue growth of just 2.21% of US companies in our set.
  • Stocks that are quantitatively similar to SXTC, based on their financial statements, market capitalization, and price volatility, are BRFS, TKC, CENX, LOMA, and MT.
  • SXTC's SEC filings can be seen here. And to visit China SXT Pharmaceuticals Inc's official web site, go to

SXTC Stock Price Chart Interactive Chart >

Price chart for SXTC

SXTC Price/Volume Stats

Current price $0.31 52-week high $1.48
Prev. close $0.34 52-week low $0.22
Day low $0.30 Volume 2,693,089
Day high $0.32 Avg. volume 3,353,773
50-day MA $0.28 Dividend yield N/A
200-day MA $0.43 Market Cap 10.63M

China SXT Pharmaceuticals, Inc. (SXTC) Company Bio

China Sxt Pharmaceuticals, Inc. engages in the development, manufacture, marketing, sales, research and development of Chinese traditional medicine. It sells Advanced TCMP, Fine TCMP and Regular TCMP products. The company sell its products under "Suxuantang" brand name. The company was founded by Zhou Feng in 2005 and is headquartered in Taizhou, China.

SXTC Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$0.31$0.02 -93%

Below please find a table outlining a discounted cash flow forecast for SXTC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that China SXT Pharmaceuticals Inc ranked in the 9th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of China SXT Pharmaceuticals Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is -2.1; that's higher than only 15.88% of US stocks in the Healthcare sector that have positive free cash flow.
  • The company's compound free cash flow growth rate over the past 1.87 years comes in at -0.24%; that's greater than merely 6.22% of US stocks we're applying DCF forecasting to.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of China SXT Pharmaceuticals Inc? See COO, EW, LUMO, TEVA, and NVST.

SXTC Latest News Stream

Event/Time News Detail
Loading, please wait...

SXTC Latest Social Stream

Loading social stream, please wait...

View Full SXTC Social Stream

Latest SXTC News From Around the Web

Below are the latest news stories about China SXT Pharmaceuticals Inc that investors may wish to consider to help them evaluate SXTC as an investment opportunity.

Hedge Funds Warming Up To China SXT Pharmaceuticals, Inc. (SXTC)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | May 29, 2020

China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.

Yahoo | March 16, 2020

What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked?

To the annoyance of some shareholders, China SXT Pharmaceuticals (NASDAQ:SXTC) shares are down a considerable 31% in...

Yahoo | December 4, 2019

Should You Worry About China SXT Pharmaceuticals, Inc.’s (NASDAQ:SXTC) ROCE?

Today we are going to look at China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) to see whether it might be an attractive...

Yahoo | November 14, 2019

Read More 'SXTC' Stories Here

SXTC Price Returns

1-mo 8.81%
3-mo 15.20%
6-mo -27.02%
1-year -62.64%
3-year N/A
5-year N/A
YTD -62.20%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching SXTC

Here are a few links from around the web to help you further your research on China SXT Pharmaceuticals Inc's stock as an investment opportunity:

China SXT Pharmaceuticals Inc (SXTC) Stock Price | Nasdaq
China SXT Pharmaceuticals Inc (SXTC) Stock Quote, History and News - Yahoo Finance
China SXT Pharmaceuticals Inc (SXTC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7924 seconds.